Liraglutide Injections Improved Shoulder Range of Motion

Researchers found that intra-articular liraglutide reduced capsular fibrosis and improved motion in a rat model.

Updated on Oct. 7, 2026 in Arthritis

Isometric editorial illustration of a glass syringe and a medical shoulder model, representing clinical medical research.
A laboratory study found that intra-articular liraglutide injections significantly reduced capsular fibrosis and improved shoulder abduction in a musculoskeletal rat model. AI Illustration. Upload story photo >

In a laboratory study of adhesive capsulitis, researchers administered intra-articular liraglutide injections to rats after six weeks of shoulder immobilization. The treatment improved abduction angles and decreased markers of fibrosis compared to saline controls.

Why it matters

The study was designed to evaluate the anti-fibrotic potential of liraglutide in a musculoskeletal model. Findings suggest a possible new therapeutic avenue for managing conditions characterized by joint stiffness and scarring.

Researchers studied 28 rats following a 6-week immobilization period. Treated groups showed significantly improved abduction angles and reduced fibronectin and alpha-smooth muscle actin levels compared to saline.

The details

Researchers induced adhesive capsulitis in 30 rats before allocating them into five treatment groups. Following a single injection of liraglutide, triamcinolone, or saline, the team observed significant reductions in capsular thickness and scarring at the three-week assessment mark.

Timeline

  1. 6 weeks was the duration of the initial shoulder immobilization phase.

  2. 3 weeks was the assessment point where improved abduction angles were observed.

The Big Picture

This discovery follows the ongoing investigation into GLP-1 receptor agonist anti-inflammatory properties. The study extends this research by testing the drug's anti-fibrotic potential within a musculoskeletal joint model.

While the study indicates potential for reducing joint scarring, these findings currently apply only to preclinical models. Further research is necessary before any human treatment options can be considered or developed.

The takeaway

This study demonstrates that liraglutide may possess anti-fibrotic properties in joint tissue. Future preclinical and clinical investigations are required to determine if these results can eventually translate into human therapeutic applications.

Further reading

Learn more about the latest research on Arthritis.

Source note: This article includes information reported by Nature.